
- Volume 0 0
Aspirin Proven Effective in Treating Migraines
Effervescent aspirin has been proven just as effective as sumatriptan or ibuprofen for treating migraine headaches, according to a recent study out of the University Essen in Germany. Researchers gave effervescent aspirin, sumatriptan (sold under the trade name Imitrex), or ibuprofen (the active ingredient in Motrin and Advil) to treat migraines of 312 patients from Germany, Italy, and Spain. Among those treated with aspirin, 53% experienced a reduction in headache severity, compared with 60% in the ibuprofen group, and 56% in the sumatriptan group. Those in the placebo group experienced just a 31% reduction of severity. After 2 hours, 27% of patients in the aspirin group were pain-free compared with 33% in the ibuprofen group, 37% in the sumatriptan group, and 12.6% in the placebo group. Further, in the aspirin group, 4.1% experienced drug-related side effects, compared with 4.5% in the placebo group; rates of side effects in the sumatriptan and ibuprofen groups were similar to placebo. These results led researchers to conclude that effervescent aspirin can provide comparable relief to sumatriptan and ibuprofen in the acute treatment of migraine attacks with good tolerability.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Articles in this issue
almost 21 years ago
Childhood Obesity May Cause Ventricle Enlargement, High Blood Pressurealmost 21 years ago
Obesity May Cause Irregular Heartbeatsalmost 21 years ago
Obesity Linked To Dementia, Brain Atrophyalmost 21 years ago
Researchers Relate Amount of Sleep to Obesity Ratesalmost 21 years ago
Acomplia Effective In Long-term Weight Lossalmost 21 years ago
COMPOUNDINGHOTLINEalmost 21 years ago
Pharmacy Fails to Warn Aspirin-Sensitive Patientalmost 21 years ago
Maxwell Group Debuts MedConferenceLivealmost 21 years ago
QuickOnline Rx Safeguards Clinical Specimensalmost 21 years ago
Consortium Launches MedsInfo-EDNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.